Patterns of response to neuroleptic treatment: factors influencing the amelioration of individual symptoms in psychotic patients.
Fifty-three patients with acute psychotic disorders (diagnosed according to DSM-III) were treated with thioridazine alone and observed during periods of up to 2 months. The amelioration of paranoid ideas and hallucinations (target symptoms) and of concentration difficulties, disorientation, reduced appetite, and reduced sleep (additional symptoms) was studied by repeated psychopathology ratings (CPRS). The patients were classified as "fast, slow or partial responders" according to the therapeutic effect registered on each target symptom. Paranoid ideas disappeared completely after less than 3 weeks of treatment in 28% of the patients (fast responders) and after more than 3 weeks in 32% (slow responders). Hallucinations disappeared significantly faster than paranoid ideas; 47% of the patients were completely free from hallucinations after less than 2 weeks of treatment (fast responders) and 38% after more than 2 weeks (slow responders). The following factors were significantly correlated to positive treatment effects of thioridazine: 1) diagnosis involving a brief history of psychotic symptoms before admission; 2) a low CPRS score for paranoid ideas on admission; 3) presence of disorientation on admission; 4) normal appetite on admission, and 5) rapidly reached optimal serum concentration of the drug.
Axelsson
R
R
Department of Psychiatry III, Lillhagen Hospital, University of Göteborg, Sweden.
Ohman
R
R
D000208:Acute Disease; D000328:Adult; D000368:Aged; D005260:Female; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013881:Thioridazine / Q000627:therapeutic use*
D013881:Thioridazine